ALKEM2022-01-012022-03-31in-bse-fin:OneOperatingExpenses01Member ALKEM2022-01-012022-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ALKEM 2021-04-01 2022-03-31 2022-04-28 INR Millions Yearly true Cash Flow Indirect Single segment The Company is exclusively engaged in pharmaceutical business 2022-01-01 2022-03-31 Audited Standalone 20063100000.00 542300000.00 20605400000.00 7660000000.00 2458900000.00 -1148700000.00 3306800000.00 130800000.00 550100000.00 5789200000.00 18747100000.00 1858300000.00 0.00 1858300000.00 324100000.00 765400000.00 1089500000.00 0.00 768800000.00 0.00 0.00 0.00 0.00 768800000.00 -17400000.00 751400000.00 0.00 0.00 239100000.00 2 6.43 6.43 0.00 0.00 6.43 6.43 1. The above audited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 12 May 2022 and subsequently approved by the Board of Directors at its meeting held on 13 May 2022. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2022. The figures for the quarter ended 31 March 2022 and 31 March 2021 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31 December 2021 and 31 December 2020 respectively, which were subjected to limited review. 2. Pursuant to the Board of Directors approval at its meeting held on 25 May 2021 on the proposed plan for restructuring of the USA business operations by bringing both the subsidiaries namely, S & B Pharma Inc, USA (“S & B”) and The PharmaNetwork LLC, USA (“TPNC”) under a single umbrella by removing intermediary holding company S & B Holdings BV, Netherlands (“S & B BV”), the Company on 4 October 2021 has consummated the transaction whereby TPNC acquired 100% shares of S&B from the Company in exchange of TPNC’s shares. Subsequently, with effect from 5 January 2022, S & B now stands dissolved and all its assets and liabilities are now transferred by TPNC as capital contribution in its wholly owned subsidiary S & B Pharma LLC. 3. During the previous year, the Company has made an assessment of the recoverable value of investment in its subsidiaries taking into account the decline in operational performance, changes in the outlook of future profitability, weaker market conditions, among other potential indicators. Accordingly an impairment loss of Rs.127.8 Million was recognised towards investment in Alkem Laboratories Corporation, Philippines, a wholly owned subsidiary of the Company in accordance with IND AS 36 ‘Impairment of assets’ and the same has been disclosed as an 'Exceptional item' in the previous year. 4. During the quarter ended 31 March 2022, the Company has paid an interim dividend of Rs. 30 (Rupees Thirty only) per equity share (1500% on the face value of Rs. 2 each) for the financial year 2021-22. The Board of Directors at its meeting held on 13 May 2022 has recommended a final dividend of Rs. 4 (Rupees Four only) per equity share (200% on the face value of Rs. 2 each) for the financial year 2021-22. 5. The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Single segment 2021-04-01 2022-03-31 Audited Standalone 88298100000.00 1998900000.00 90297000000.00 28497500000.00 10770400000.00 -3609000000.00 14344900000.00 379000000.00 2189800000.00 20190700000.00 72763300000.00 17533700000.00 0.00 17533700000.00 3038200000.00 -917000000.00 2121200000.00 0.00 15412500000.00 0.00 0.00 0.00 0.00 15412500000.00 -48600000.00 15363900000.00 0.00 0.00 239100000.00 2 87197500000.00 128.90 128.90 0.00 0.00 128.90 128.90 Other expenses 5789200000.00 Other expenses 20190700000.00 379039000.00 -4624800000.00 -1728626000.00 0.00 407855000.00 0.00 0.00 0.00 0.00 3194975000.00 0.00 0.00 0.00 2189800000.00 0.00 478835000.00 0.00 0.00 0.00 -199662000.00 36800000.00 1095880000.00 0.00 0.00 0.00 0.00 -156573000.00 0.00 0.00 -1191837000.00 16341863000.00 0.00 0.00 0.00 3348513000.00 0.00 12993350000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 105927000.00 2448736000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 304013000.00 0.00 0.00 0.00 0.00 0.00 36800000.00 846667000.00 0.00 -15538043000.00 0.00 -16693372000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8928996000.00 0.00 0.00 121479000.00 4184800000.00 256778000.00 0.00 0.00 4365939000.00 665917000.00 0.00 665917000.00 152200000.00 818117000.00